Akebia Therapeutics, Inc. (AKBA) Stock Profile — Insider Trades & Financials

Revenue$49.1M

Net Income-$8.9M

EPS$-0.07

Market Cap$212.8M

Price Performance

Historical data including institutional events

Company Profile

John Butler

CEO & Executive Director

Company profile for Akebia Therapeutics, Inc. (AKBA) stock, with a description, list of executives, contact details and other key facts.

Founded: 2007
Employees: 1
Headquarters: CAMBRIDGE, MA, United States
Website: akebia.com

Peer ComparisonRevenue ($B)

▾

Loading company sections...

Revenue$49.1M

Net Income-$8.9M

EPS$-0.07

Market Cap$212.8M

Price Performance

Historical data including institutional events

Company Profile

John Butler

CEO & Executive Director

Company profile for Akebia Therapeutics, Inc. (AKBA) stock, with a description, list of executives, contact details and other key facts.

Founded: 2007
Employees: 1
Headquarters: CAMBRIDGE, MA, United States
Website: akebia.com

Peer ComparisonRevenue ($B)

▾

Cross-Section Event Timeline

INSIDERS · CONGRESS · EARNINGS

INSIDER GRANT / AWARDPhilip J. Vickers (Director) GRANT / AWARD AKBAApr 1, 2026

INSIDER GRANT / AWARDLeanne M. Zumwalt (Director) GRANT / AWARD AKBAJun 17, 2026

INSIDER GRANT / AWARDMichael W. Rogers (Director) GRANT / AWARD AKBAJun 17, 2026

INSIDER GRANT / AWARDAdrian Adams (Director) GRANT / AWARD AKBAJun 17, 2026

INSIDER GRANT / AWARDCynthia Smith (Director) GRANT / AWARD AKBAJun 17, 2026

INSIDER GRANT / AWARDMyles Wolf (Director) GRANT / AWARD AKBAJun 17, 2026

INSIDER GRANT / AWARDRon Frieson (Director) GRANT / AWARD AKBAJun 17, 2026

INSIDER SELLErik Ostrowski (SVP, CFO, CBO & Treasurer) SELL AKBAJun 29, 2026

INSIDER EXERCISE / CONVERSIONJohn P. Butler (CEO and President) EXERCISE / CONVERSION AKBAAug 6, 2026

⚡

Core Efficiency

ROE?

-35.61%

ROA?

-2.55%

D/E Ratio?

12.98

Op. Margin?

-12.88%

📊

Profitability Ratios

Net Margin?

-18.13%

Current Ratio?

1.43

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Nov 14, 2026 (in 32 days)

Quarterly Report (10-Q) — Based on filing pattern

Nov 14, 2026

Predicted10-Q

Aug 5, 2026

10-QQ2 202636d after period end

May 7, 2026

10-QQ1 202637d after period end

Feb 26, 2026

10-KQ4 202557d after period end

Feb 26, 2026

10-KFY 202557d after period end

Nov 10, 2025

10-QQ3 202541d after period end

Aug 7, 2025

10-QQ2 202538d after period end

May 8, 2025

10-QQ1 202538d after period end

Mar 13, 2025

10-KQ4 202472d after period end

Data Freshness

Financial Data

2mo ago

Latest filing: 2026-08-05

SEC Metadata

2mo ago

Latest filing: 2026-08-05

Loading company sections...

Akebia Therapeutics, Inc.

Price Performance

Company Profile

Akebia Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Akebia Therapeutics, Inc.

Price Performance

Company Profile

The morning brief, before the bell.

Akebia Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness

Recent Insider Trades